van der Laan Siem, Meijer Onno C
Division of Medical Pharmacology, Leiden/Amsterdam Centre for Drug Research (LACDR), PO Box 9502, 2300 RA Leiden, The Netherlands.
Eur J Pharmacol. 2008 May 13;585(2-3):483-91. doi: 10.1016/j.ejphar.2008.01.060. Epub 2008 Mar 18.
Glucocorticoid hormones are important regulators of homeostasis. They are used clinically as highly effective anti-inflammatory compounds and have been prescribed for more than fifty years for a variety of conditions. They mediate their genomic actions by binding to two different intracellular receptors in target cells. The pharmacology of glucocorticoids largely depends on ligand concentration and receptor expression levels in target tissue. However, their genomic actions also critically depend on coactivators and corepressors recruitment. We discuss how various non-receptor factors affect glucocorticoid potency and efficacy with respect to their genomic effects. Differential recruitment of coregulators may account for many ligand- and cell-specific effects of glucocorticoids. This is best illustrated by the recent identification of selective glucocorticoid receptor agonists that induce distinct conformational changes to the receptors resulting in altered protein-protein interactions and consequently different regulation of gene expression. We conclude that these new molecular insights will contribute to the design of safer glucocorticoids that retain full pharmacological properties with reduced side-effects.
糖皮质激素是体内稳态的重要调节因子。它们在临床上作为高效抗炎化合物使用,五十多年来一直被用于治疗各种病症。它们通过与靶细胞中的两种不同细胞内受体结合来介导其基因组作用。糖皮质激素的药理学很大程度上取决于靶组织中的配体浓度和受体表达水平。然而,它们的基因组作用也严重依赖于共激活因子和共抑制因子的募集。我们讨论了各种非受体因子如何影响糖皮质激素在基因组效应方面的效力和功效。共调节因子的差异募集可能解释了糖皮质激素的许多配体特异性和细胞特异性效应。最近鉴定出的选择性糖皮质激素受体激动剂能诱导受体发生不同的构象变化,导致蛋白质-蛋白质相互作用改变,从而对基因表达产生不同的调节,这一点得到了最好的说明。我们得出结论,这些新的分子见解将有助于设计出更安全的糖皮质激素,在保留完整药理特性的同时减少副作用。